Cargando…
Imaging biomarkers of contrast-enhanced computed tomography predict survival in oesophageal cancer after definitive concurrent chemoradiotherapy
BACKGROUND: This study aimed to evaluate the predictive potential of contrast-enhanced computed tomography (CT)-based imaging biomarkers (IBMs) for the treatment outcomes of patients with oesophageal squamous cell carcinoma (OSCC) after definitive concurrent chemoradiotherapy (CCRT). METHODS: Altoge...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805131/ https://www.ncbi.nlm.nih.gov/pubmed/33436018 http://dx.doi.org/10.1186/s13014-020-01699-w |
_version_ | 1783636256116178944 |
---|---|
author | Zeng, Chengbing Zhai, Tiantian Chen, Jianzhou Guo, Longjia Huang, Baotian Guo, Hong Liu, Guozhi Zhuang, Tingting Liu, Weitong Luo, Ting Wu, Yanxuan Peng, Guobo Li, Derui Chen, Chuangzhen |
author_facet | Zeng, Chengbing Zhai, Tiantian Chen, Jianzhou Guo, Longjia Huang, Baotian Guo, Hong Liu, Guozhi Zhuang, Tingting Liu, Weitong Luo, Ting Wu, Yanxuan Peng, Guobo Li, Derui Chen, Chuangzhen |
author_sort | Zeng, Chengbing |
collection | PubMed |
description | BACKGROUND: This study aimed to evaluate the predictive potential of contrast-enhanced computed tomography (CT)-based imaging biomarkers (IBMs) for the treatment outcomes of patients with oesophageal squamous cell carcinoma (OSCC) after definitive concurrent chemoradiotherapy (CCRT). METHODS: Altogether, 154 patients with OSCC who underwent definitive CCRT were included in this retrospective study. All patients were randomised to the training cohort (n = 99) or the validation cohort (n = 55). Pre-treatment contrast-enhanced CT scans were obtained for all patients and used for the extraction of IBMs. An IBM score, was constructed by using the least absolute shrinkage and selection operator with Cox regression analysis, which was equal to the log-partial hazard of the Cox model in the training cohort and tested in the validation cohort. IBM nomograms were built based on IBM scores for individualised survival estimation. Finally, a decision curve analysis was performed to estimate the clinical usefulness of the nomograms. RESULTS: Altogether, 96 IBMs were extracted from each contrast-enhanced CT scan. IBM scores were constructed from 11 CT-based IBMs for overall survival (OS) and 8 IBMs for progression-free survival (PFS), using the LASSO-Cox regression method in the training cohort. Multivariate analysis revealed that IBM score was an independent prognostic factor correlated with OS and PFS. In the training cohort, the C-indices of IBM scores were 0.734 (95% CI 0.664–0.804) and 0.658 (95% CI 0.587–0.729) for OS and PFS, respectively. In the validation cohort, C-indices were 0.672 (95% CI 0.578–0.766) and 0.666 (95% CI 0.574–0.758) for OS and PFS, respectively. Kaplan–Meier survival analysis showed a significant difference between risk subgroups in the training and validation cohorts. Decision curve analysis confirmed the clinical usefulness of the IBM score. CONCLUSIONS: The IBM score based on pre-treatment contrast-enhanced CT could predict the OS and PFS for patients with OSCC after definitive CCRT. Further multicentre studies with larger sample sizes are warranted. |
format | Online Article Text |
id | pubmed-7805131 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-78051312021-01-14 Imaging biomarkers of contrast-enhanced computed tomography predict survival in oesophageal cancer after definitive concurrent chemoradiotherapy Zeng, Chengbing Zhai, Tiantian Chen, Jianzhou Guo, Longjia Huang, Baotian Guo, Hong Liu, Guozhi Zhuang, Tingting Liu, Weitong Luo, Ting Wu, Yanxuan Peng, Guobo Li, Derui Chen, Chuangzhen Radiat Oncol Research BACKGROUND: This study aimed to evaluate the predictive potential of contrast-enhanced computed tomography (CT)-based imaging biomarkers (IBMs) for the treatment outcomes of patients with oesophageal squamous cell carcinoma (OSCC) after definitive concurrent chemoradiotherapy (CCRT). METHODS: Altogether, 154 patients with OSCC who underwent definitive CCRT were included in this retrospective study. All patients were randomised to the training cohort (n = 99) or the validation cohort (n = 55). Pre-treatment contrast-enhanced CT scans were obtained for all patients and used for the extraction of IBMs. An IBM score, was constructed by using the least absolute shrinkage and selection operator with Cox regression analysis, which was equal to the log-partial hazard of the Cox model in the training cohort and tested in the validation cohort. IBM nomograms were built based on IBM scores for individualised survival estimation. Finally, a decision curve analysis was performed to estimate the clinical usefulness of the nomograms. RESULTS: Altogether, 96 IBMs were extracted from each contrast-enhanced CT scan. IBM scores were constructed from 11 CT-based IBMs for overall survival (OS) and 8 IBMs for progression-free survival (PFS), using the LASSO-Cox regression method in the training cohort. Multivariate analysis revealed that IBM score was an independent prognostic factor correlated with OS and PFS. In the training cohort, the C-indices of IBM scores were 0.734 (95% CI 0.664–0.804) and 0.658 (95% CI 0.587–0.729) for OS and PFS, respectively. In the validation cohort, C-indices were 0.672 (95% CI 0.578–0.766) and 0.666 (95% CI 0.574–0.758) for OS and PFS, respectively. Kaplan–Meier survival analysis showed a significant difference between risk subgroups in the training and validation cohorts. Decision curve analysis confirmed the clinical usefulness of the IBM score. CONCLUSIONS: The IBM score based on pre-treatment contrast-enhanced CT could predict the OS and PFS for patients with OSCC after definitive CCRT. Further multicentre studies with larger sample sizes are warranted. BioMed Central 2021-01-12 /pmc/articles/PMC7805131/ /pubmed/33436018 http://dx.doi.org/10.1186/s13014-020-01699-w Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Zeng, Chengbing Zhai, Tiantian Chen, Jianzhou Guo, Longjia Huang, Baotian Guo, Hong Liu, Guozhi Zhuang, Tingting Liu, Weitong Luo, Ting Wu, Yanxuan Peng, Guobo Li, Derui Chen, Chuangzhen Imaging biomarkers of contrast-enhanced computed tomography predict survival in oesophageal cancer after definitive concurrent chemoradiotherapy |
title | Imaging biomarkers of contrast-enhanced computed tomography predict survival in oesophageal cancer after definitive concurrent chemoradiotherapy |
title_full | Imaging biomarkers of contrast-enhanced computed tomography predict survival in oesophageal cancer after definitive concurrent chemoradiotherapy |
title_fullStr | Imaging biomarkers of contrast-enhanced computed tomography predict survival in oesophageal cancer after definitive concurrent chemoradiotherapy |
title_full_unstemmed | Imaging biomarkers of contrast-enhanced computed tomography predict survival in oesophageal cancer after definitive concurrent chemoradiotherapy |
title_short | Imaging biomarkers of contrast-enhanced computed tomography predict survival in oesophageal cancer after definitive concurrent chemoradiotherapy |
title_sort | imaging biomarkers of contrast-enhanced computed tomography predict survival in oesophageal cancer after definitive concurrent chemoradiotherapy |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805131/ https://www.ncbi.nlm.nih.gov/pubmed/33436018 http://dx.doi.org/10.1186/s13014-020-01699-w |
work_keys_str_mv | AT zengchengbing imagingbiomarkersofcontrastenhancedcomputedtomographypredictsurvivalinoesophagealcancerafterdefinitiveconcurrentchemoradiotherapy AT zhaitiantian imagingbiomarkersofcontrastenhancedcomputedtomographypredictsurvivalinoesophagealcancerafterdefinitiveconcurrentchemoradiotherapy AT chenjianzhou imagingbiomarkersofcontrastenhancedcomputedtomographypredictsurvivalinoesophagealcancerafterdefinitiveconcurrentchemoradiotherapy AT guolongjia imagingbiomarkersofcontrastenhancedcomputedtomographypredictsurvivalinoesophagealcancerafterdefinitiveconcurrentchemoradiotherapy AT huangbaotian imagingbiomarkersofcontrastenhancedcomputedtomographypredictsurvivalinoesophagealcancerafterdefinitiveconcurrentchemoradiotherapy AT guohong imagingbiomarkersofcontrastenhancedcomputedtomographypredictsurvivalinoesophagealcancerafterdefinitiveconcurrentchemoradiotherapy AT liuguozhi imagingbiomarkersofcontrastenhancedcomputedtomographypredictsurvivalinoesophagealcancerafterdefinitiveconcurrentchemoradiotherapy AT zhuangtingting imagingbiomarkersofcontrastenhancedcomputedtomographypredictsurvivalinoesophagealcancerafterdefinitiveconcurrentchemoradiotherapy AT liuweitong imagingbiomarkersofcontrastenhancedcomputedtomographypredictsurvivalinoesophagealcancerafterdefinitiveconcurrentchemoradiotherapy AT luoting imagingbiomarkersofcontrastenhancedcomputedtomographypredictsurvivalinoesophagealcancerafterdefinitiveconcurrentchemoradiotherapy AT wuyanxuan imagingbiomarkersofcontrastenhancedcomputedtomographypredictsurvivalinoesophagealcancerafterdefinitiveconcurrentchemoradiotherapy AT pengguobo imagingbiomarkersofcontrastenhancedcomputedtomographypredictsurvivalinoesophagealcancerafterdefinitiveconcurrentchemoradiotherapy AT liderui imagingbiomarkersofcontrastenhancedcomputedtomographypredictsurvivalinoesophagealcancerafterdefinitiveconcurrentchemoradiotherapy AT chenchuangzhen imagingbiomarkersofcontrastenhancedcomputedtomographypredictsurvivalinoesophagealcancerafterdefinitiveconcurrentchemoradiotherapy |